News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Eisai Company, Ltd. Announce Japan Launch of Oral Anticoagulant Warfarin Granules 0.2%
December 5, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Tokyo, Nov 30, 2011 (JCN Newswire) - Eisai Co., Ltd. announced today that it will launch Warfarin Granules 0.2%, a new formulation of the company's oral anti-coagulant Warfarin (warfarin potassium), on December 1 in Japan.
Twitter
LinkedIn
Facebook
Email
Print
Asia
MORE ON THIS TOPIC
Government
FDA Freezes Trials Shipping Cells to China, ‘Other Hostile Countries’
June 20, 2025
·
2 min read
·
Tristan Manalac
Antibody-drug conjugate (ADC)
NextCure Joins China-ADC Gold Rush with $745M Simcere Deal
June 16, 2025
·
1 min read
·
Dan Samorodnitsky
Autoimmune disease
Cullinan Bets $700M+ in Back-Heavy China Deal for Autoimmune T Cell Engager
June 5, 2025
·
2 min read
·
Tristan Manalac
Lung Cancer
Summit’s Bispecific Misses Survival Endpoint in Global Phase III Trial but Analysts Remain Optimistic
May 30, 2025
·
3 min read
·
Nick Paul Taylor
